NuvOx LLC: Clinical Trials

9 trials sponsored by NuvOx LLC, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting, 1 available, 1 enrolling by invitation. 4 Phase 1, 3 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 14Completed 2, Recruiting 1, Withdrawn 1
Phase 23Active not recruiting 1, Not yet recruiting 1, Unknown 1
Phase 31Unknown 1

Follow NuvOx LLC: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic
Glioblastoma (GBM)
Enrolling by invitationNuvOx LLC402025-12-082026-02-18
NanO2 in Large VessEL Occlusion Stroke (NOVEL)
NanO2TM, Sodium Chloride 0.9% Intravenous - Stroke Acute
Phase 2Not yet recruitingNHS Greater Glasgow and Clyde1722025-05-012025-04-04
A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress
dodecafluoropentane (0.025 mL/kg), dodecafluoropentane (0.032 mL/kg), dodecafluoropentane (0.050 mL/kg) - Mild Respiratory Distress
Phase 1RecruitingNuvOx LLC182025-03-132026-01-28
NanO2 for Large Vessel Occlusion Stroke
Placebo, dodecafluoropentane emulsion (DDFPe) - Ischemic Stroke
Phase 2 / Phase 3UnknownNuvOx LLC3002023-04-012022-05-25
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
NanO2TM, Placebo Saline Infusion - Glioblastoma Multiforme
Phase 2Active not recruitingNuvOx LLC872023-03-312026-08-06
A Phase Ib Study of NVX-508 in Sickle Cell Disease
NVX-508 - Sickle Cell Disease
Phase 1WithdrawnAmma Owusu-Ansah, MD2018-07-012018-07-16
A Phase Ib/II in Patients With Acute Ischemic Stroke
0.05 mL/kg DDFPe, 0.05 mL/kg Placebo, 0.10 mL/kg DDFPe - Ischemic Stroke
Phase 1CompletedNuvOx LLC242017-02-012021-09-24
The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma
NVX-108 - Glioblastoma Multiforme
Phase 1CompletedNuvOx LLC112014-05-012019-02-28
NuvOx Expanded Access
NanO₂ - Glioblastoma, Respiratory Distress Syndrom
AvailableNuvOx LLC2026-08-05

Conditions studied

Glioblastoma (4)  ·  Ischemic Stroke (3)  ·  Anemia, Sickle Cell (1)  ·  Dyspnea (1)  ·  Stroke (1)

Interventions

perfluoropentane (3)  ·  Sodium Chloride (1)

Countries

United States (3)  ·  Australia (1)  ·  Canada (1)  ·  United Kingdom (1)

Top investigators

Amma T Owusu-Ansah, MD (1)  ·  Jason Lickliter, MBBSPhDFRACP (1)  ·  Sanjeeva Onteddu, MD (1)  ·  William Culp, MD (1)

Results publications

PMID 31349978, PMID 37609003

NIH funding

R44CA298498 (1)